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Abstract
Background: Patients with Acute Hypercapnic Respiratory Failure (AHRF) who are unresponsive to appropriate medical
treatment, are often treated with Noninvasive Positive Pressure Ventilation (NPPV). Clinical predictors of the outcome of this
treatment are scarce. Therefore, we evaluated the role of the biomarkers IL-8 and GDF-15 in predicting 28-day mortality in
patients with AHRF who receive treatment with NPPV.
Methods: The study population were 46 patients treated with NPPV for AHRF. Clinical and background data was registered
and blood samples taken for analysis of inflammatory biomarkers. IL-8 and GDF-15 were selected for analysis, and related to
risk of 28-day mortality (primary endpoint) using Cox proportional hazard models adjusted for gender, age and various
clinical parameters.
Results: Of the 46 patients, there were 3 subgroup in regards to primary diagnosis: Acute Exacerbation of COPD (AECOPD,
n= 34), Acute Heart Failure (AHF, n= 8) and Acute Exacerbation in Obesity Hypoventilation Syndrome (AEOHS, n= 4). There
was significant difference in the basic characteristic of the subgroups, but not in the clinical parameters that were used in
treatment decisions. 13 patients died within 28 days of admission (28%). The Hazard Ratio for 28-days mortality per 1-SD
increment of IL-8 was 3.88 (95% CI 1.86–8.06, p< 0.001). When IL-8 values were divided into tertiles, the highest tertile had
a significant association with 28 days mortality, HR 10.02 (95% CI 1.24–80.77, p for trend 0.03), compared with the lowest
tertile. This correlation was maintained when the largest subgroup with AECOPD was analyzed. GDF-15 was correlated in
the same way, but when put into the same model as IL-8, the significance disappeared.
Conclusion: IL-8 is a target to explore further as a predictor of 28 days mortality, in patients with AHRF treated with NPPV.
Keywords: Acute Respiratory Failure, Noninvasive Positive Pressure Ventilation, Short-time Mortality, Interleukin-8, Growth
Differentiation Factor 15
Background
As Chronic Obstructive Lung Disease continues to be a
leading cause of mortality and morbidity worldwide, the
importance of choosing the most appropriate treatment
for each patient is vital [1, 2]. In Acute Hypercapnic
Respiratory Failure (AHRF) due to Acute Exacerbation
of COPD (AECOPD), Noninvasive Positive Pressure
Ventilation (NPPV) has been shown to reduce the need
for endotracheal intubation, the length of hospital stay,
and the in-hospital mortality rate, in patients who are
unresponsive to acute appropriate medical therapy
[3–8]. Sixty-day survival benefit has even been shown
in patients with acute-on-chronic respiratory failure
[9]. Patient selection is important, and the treatment is
most effective in the early stages of acidosis [10–13].
Factors that have been show to predict NPPV failure in
patients with AECOPD (resulting in endotracheal intub-
ation or death) are severe acidosis (pH <7.25), low Glas-
gow Coma Scale scores, high respiratory rate and high
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APACHE-II score [14]. Even lack of improvement within
the first hour after initiation of NPPV is a negative prog-
nostic factor in patients with various underlying causes of
AHRF [15].
NPPV is even effective in some other causes of respira-
tory failure, such as acute heart failure, pneumonia in
COPD patients and infections in immunocompromised
patients [16–20]. Berg et al. stated in a review article, that
in patients with acute heart failure treated with nonvasive
ventilation, many studies show some degree of benefit in
regards to relief of respiratory distress, lower intubation
rates or decreased mortality. There is no difference be-
tween NPPV and CPAP (continuous positive airway pres-
sure), the latter being the first treatment option in acute
cardiogenic pulmonary edema, but NPPV is recom-
mended if there is any evidence of hypercapnia or if the
patient remains in distress despite treatment with CPAP
[21] Both NPPV and CPAP are also commonly used in ex-
acerbations of obesity hypoventilation syndrome [22]. A
comparison of NPPV treatment in patients with AHRF in
AECOPD or Obesity Hypoventilation Syndrome (OHS)
showed similar effectiveness regarding survival, in-
hospital mortality, and length of hospital stay [23]. There
is a lack of randomized clinical trials for OHS patients
with AHRF, but the treatment is considered safe and ef-
fective, even if acidosis prevails generally longer than in
patients with AECOPD [24].
COPD is associated with low-grade systemic inflam-
mation. The search for biomarkers to predict outcome
in COPD patients, both during exacerbations and in
stable condition, has been extensive in the last few years
[25, 26]. To our knowledge, no study has been published
that has evaluated the roll of inflammatory biomarkers
to predict short term mortality in patients with AHRF
(with various underlying causes) treated with NPPV.
In order to improve risk stratification of patients with
acute dyspnea, we recently assessed inflammatory
biomarkers and their predicting value for mortality in pa-
tients that came to the ER with acute dyspnea, and found
that in this group, Interleukin-8 (IL-8) and Growth Differ-
entiation Factor 15 (GDF-15) strongly and independently
predict 90-days mortality, individually and as an aggre-
gated score [27]. IL-8 is produced by various cells in the
inflammatory pathway. Among other things, it induces
the migration of neutrophils to the airway [28]. GDF-15 is
a regulatory protein in the inflammatory pathway and is
also produced by various cells in response to oxidative
and inflammatory factors [29]. Based on the strong asso-
ciation between IL-8 and GDF-15 and mortality in pa-
tients with acute dyspnea in our previously published
study [27], we hypothesize that these two inflamma-
tory markers may add clinically meaningful informa-




During the period January 2014 to June 2014 we enrolled
adult patients with acute respiratory failure that had clin-
ical indication for treatment with NPPV according to local
clinical guidelines, in the Intermediate Emergency Care
Department at Skane University Hospital in Malmö,
Sweden. The hospital serves a catchment area of approxi-
mately 400,000 inhabitants. We did not perform a power
calculation as no prior suggested effect size for the associ-
ation between IL-8 and GDF-15 on 28-day mortality in
AHRF patients on NPPV treatment exist, on which the
power calculation could be based. Written informed con-
sent was obtained from all patients or their next of kin.
We included all patients that received treatment with
NPPV for AHRF, decided by the attending physicians
and regardless of the underlying disease. Patients with
neurological disease or sepsis as the main cause of
respiratory failure were excluded. Participation did not
intervene with the treatment itself and the research per-
sonal was not responsible for the medical treatment in
any way. Thus, the study was observational and
prospective. As the clinical value of NPPV treatment in
AHRF is nonmistakable according to various studies, it
was not possible to have a control group deprived of the
treatment [5, 8, 9, 16, 19, 23].
The study was approved by the Regional Ethics Board
of Lund, Sweden and followed the precepts established
by the Declaration of Helsinki.
Clinical parameters and follow-up
Vital parameters were obtained before and during the
treatment at several previously decided time points (0, 1,
4, and 12 h after the start of treatment and venous blood
samples and arterial blood gases (ABG) were taken. Vital
parameters recorded were body temperature, peripheral
oxygen saturation (SpO2), heart rate, blood pressure, re-
spiratory rate and degree of consciousness according to
the “Reaction Level Scale” (RLS) [30]. The ABGs were an-
alyzed immediately on a ABL800 Flex (Radiometer,
Copenhagen, Denmark), while the venous blood samples
were frozen and stored at −80 °C for later analysis of bio-
markers, after having separated serum and plasma.
All the patients received Bilevel NPPV treatment with
Trilogy100 and a suitable NPPV mask (Respironics,
Murrysville, Pennsylvania/USA), using S/T mode. Expira-
tory positive airway pressure (EPAP) was set to 5 cm H2O.
Inspiratory positive airway pressure (IPAP) was automatic-
ally regulated with average volume assured pressure sup-
port (AVAPS), so that a pressure between 10 and 25 cm
H2O was applied to obtain a goal tidal volume of 8 ml/kg.
Backup respiratory rate was set to 10 breaths/min. Oxygen
was applied as needed with a goal SpO2 of 88–90%. The pa-
tients were monitored closely during the treatment. The
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treatment was only stopped for shorter periods, for ex-
ample during meals. The physicians on call decided when
the treatment was discontinued. Details about treatment
length and installations was obtained from the Directview
Program (Respironics, Murrysville, Pennsylvania/USA).
The patients consented to have their medical history
and current medication obtained through the journal
database of the hospital. Smoking habits, employment his-
tory and marital status was obtained through interview.
Biomarker measurement
Based on our previous findings in risk stratification of pa-
tients with acute dyspnea [27], we selected to study IL-8
and GDF-15 which were measured in frozen plasma sam-
ples using the Proseek Multiplex CVD 1 biomarker panel
(Olink Bioscience, Uppsala, Sweden). The method is a
multiplex immunoassay based on a Proximity Extension
Assay [31]. All assay characteristics including detection
limits and measurements of assay performance and valida-
tions are available from the manufacturer’s webpage [32].
Endpoint
The primary endpoint in the current study was defined
as death within 28 days after admission to the ER. We
confirmed deaths and date of death using the Swedish
National civil registry.
Statistical analysis
All statistical analysis was performed with IBM SPSS
statistics version 21 (SPSS Inc., Chigago, IL, USA). In
univariate analyses we used Kruskal-Wallis test to
analyze continuous variables, and expressed data as me-
dians and interquartile ranges. For categorical variables,
Fishers exact test was used and data was expressed as
numbers and percentages. We used Cox proportional
hazards model to relate baseline variables to risk of
death during 28 days of follow-up. Biomarkers levels
were transformed with the natural logarithm and
expressed as hazard ratios (95% confidence interval) on
a standardized scale (per 1 standard deviation incre-
ment) as well as in tertiles, with the lowest tertile as the
reference group. We adjusted for age and gender (model
1) and age, gender and C-reactive protein (CRP) (model
2) and also entered multiple potential confounders using
backward stepwise Wald selection with a retention P-
value >0.10 (model 3). Finally, crude Kaplan-Meier plots
for tertiles of IL-8 levels were plotted. All tests were




Fifty-one patients were enrolled during the study time,
but five patients were excluded because of withdrawal of
consent (n = 3), presence of neurological disease (n = 1)
and sepsis (n = 1) as main underlying causes of AHRF,
leaving forty-six patients in the analysis. No patient was
intubated during the hospital stay. Chest radiographies
were performed bedside on 39 patients (85%). 2 patients
had radiological evidence of possible consolidation, both
of which survived the follow up time of 28 days. There
was no significant correlation between radiologial
evidence of heart failure or consolidation, and 28 days
mortality (data not shown). All patients were evaluated
by attending physicians regarding vital status, and in 33
patients (72%), the “Do Not Resuscitate” order was made
and recorded in the medical journal, according to local
guidelines. Twenty-four patients (52%) were evaluated
not to be eligible for ICU ward. Thirteen patients died
within 28 days after admission (28%), of whom 10 pa-
tients died during the hospital stay. The median length
of stay was 7 days (IQR 4–11 days).
Before analysis of data, the medical records were ex-
amined by an internist and a primary discharge diagno-
sis was made. There were 3 subgroups of patients in
regards to primary diagnosis: Acute Exacerbation of
COPD (AECOPD), Acute Heart Failure (AHF) and
Acute Respiratory failure in OHS (AEOHS). To evaluate
if there was difference between the groups, clinical char-
acteristics were compared between the groups (Table 1).
There were significant group differences in age, BMI and
smoking status. While the difference between the sub-
groups lay within the basic characteristics of the group
population, but not in regards of variables which deter-
mined NPPV treatment, the assumption was made that
all results could be analyzed as one group of patients
with AHRF. Analyses were nonetheless also made on the
largest subgroup of patients with AECOPD, as described
below.
IL-8 and GDF-15
The biomarkers IL-8 and GDF-15 at admission before
treatment was started, showed significant association
with 28 days mortality through adjusted Cox propor-
tional hazard models 1 (age and gender adjusted) and 2
(age, gender and CRP adjusted) (Tables 2 and 3). Each 1
SD increment of IL-8 was associated with almost four-
fold increased risk of 28 days mortality, and for GDF-15
the increase in risk was almost threefold (Tables 2 and
3). Even CRP alone (adjusted for age and gender) was
analyzed in model 2, and was an independent risk factor
for 28 days mortality (HR 1.61 (1.08–2.41), p 0.02). In
model 3, where additional parameters (BMI and blood
analysis (pH, pO2, pCO2, lactate) as well as respiratory
rate at start of treatment and primary discharge diagno-
sis) were entered in a backward stepwise elimination
model (data missing on n = 13), both IL-8 (p = 0.015)
and GDF-15 (p = 0.008) remained significantly related to
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risk of 28-day mortality. The independent significant as-
sociation between IL-8 or GDF-15 and 28-day mortality
remained after exclusion of the two patients with con-
solidation on chest radiograph (data not shown).
IL-8 tertiles were entered into model 1 and 2 adjusted
Cox proportional hazard model, patients in the highest
tertile showed a significant 10-fold and 13-fold, respect-
ively, increased risk of 28 days mortality, as compared to
the lowest tertile (Table 2). The event rate in IL-8 tertiles
according to a Kaplan-Meier plot is shown in Fig. 1.
When GDF-15 tertiles were analyzed in the same man-
ner, there was no significant association in model 1, but
in model 2 there was a significant association with a 2,5
fold increased risk for mortality for the highest tertile as
compared to the lowest (Table 3).
To evaluate if both IL-8 and GDF-15 were independ-
ent risk factors, we simultaneously entered them as con-
tinuous variables into model 1 and found that only IL-8
remained significantly associated, with HR 3.38 (95% CI
1.35–8.43, p = 0.009) per 1 SD increment.
Being the largest group, we then analyzed the group of
patients with AECOPD as their primary diagnosis (n = 34)
separately. Both IL-8 and GDF-15 at admission showed
significant association with 28 days mortality in models
1–2 with approximately fourfold and threefold increased
risk per 1 SD increment (Table 4). When simultaneously
entered into model 1, only IL-8 remained significantly as-
sociated with HR 4.31 (95% CI 1.57–11.84, p = 0.005).
Discussion
Our findings suggest that IL-8 is a target to explore fur-
ther as a biomarker in predicting 28 days mortality, in
patients with AHRF (Acute Hypercapnic Respiratory
Failure) and AECOPD (Acute Exacerbation of COPD)
who receive treatment with NPPV (Noninvasive Positive
Pressure Ventilation). The results were driven by COPD
Table 1 Characteristics of the patients, as a whole group and divided into subgroups
Whole group AECOPD AHF AEOHS P valueb
General characteristics
Number of patients 46 34 8 4
Age years: median (IQR) 77.1 (68.7–84.0) 76.9 (68.8–83.9) 82.3 (77.7–86.8) 65.4 (60.5–73.0) 0.035
BMI kg/m2: median (IQR) 23.4 (20.5–36.1) 24.0 (18.8–28.2) 27.7 (21.7–39.2) 46.6 (39.3–55.2) 0.004
Gender female % 65% (30/46) 65% (22/34) 63% (5/8) 75% (3/4) 0.054
Active or ex-smokers % 87% (40/46) 97% (33/34) 63% (5/8) 50% (2/4) <0.001
FEV1%: median (IQR) 31 (24–43) 29 (22–36) 47a 43a 0.058
Variables related to AHRF
pH: median (IQR) 7.28 (7.24–7.36) 7.31 (7.24–7.37) 7.24 (7.10–7.31) 7.30 (7.25–7.35) 0.17
pO2 kPa: median (IQR) 7.45 (6.33–8.73) 6.85 (6.10–8.48) 7.50 (5.60–9.58) 8.40 (8.23–10.68) 0.24
pCO2 kPa: median (IQR) 8.75 (7.78–10.5) 8.90 (7.78–10.35) 8.05 (6.38–10.73) 10.05 (8.45–11.73) 0.30
Respiratory rate bpm: median (IQR) 26 (20–29) 26 (20–29) 24 (22–29) 25 (21–27) 0.89
CRP mg/L: median (IQR) 15.5 (8.3–76.5) 36.5 (9.7–93.0) 8.7 (6.4–11.0) 12.5 (7.5–37.0) 0.076
Lactate mmol/L: median (IQR) 1.40 (0.80–2.75) 1.10 (0.80–2.10) 3.80 (2.78–5.63) 1.20 (0.80–2.35) 0.09
NPPV use first 4 h: median (IQR) 3.57 (3.50–4.00) 3.67 (3.50–4.00) 3.50 (2.50–4.00) 3.75 (3.50–4.00) 0.67
IQR interquartile range, AECOPD acute exacerbation of COPD, AHF acute heart failure, AEOHS acute exacerbation of obesity hypoventilation syndrome, BMI body
mass index, FEV1 forced expiratory volume in 1 s, CRP C-reactive protein, NPPV noninvasive positive pressure ventilation
avariable number too small to analyse IQR
bWe used Kruskal-Wallis test for all but gender and smoking status, there we used Fisher´s exact test
Table 2 Relationship between Interleukin-8 (IL-8) and risk of 28-day mortality
IL-8 on admission vs 28 days follow-up death (Model 1 and 2)
Continuous IL-8 analysis
(per SD increment)
P-value Tertile 1 Tertile 2 Tertile 3 P for trend
N/N eventsb 46/13 15/1 16/3 15/9
HR (95% CI) (age and gender adjusted) 3.88 (1.86–8.06) <0.001 1.0 (ref) 2.79 (0.29–26.89) 10.02 (1.24–80.77) 0.009
HR (95% CI) (age, gender and CRP adjusted)a 3.76 (2.02–7.03) <0.001 1.0 (ref) 3.11 (0.32–29.93) 13.47 (1.70–106.91) 0.003
SD standard deviation, HR hazard ratio, CI confidence interval, CRP C-reactive protein
aBackward elimination model
bdeath within 28 days from admission
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patients, so further studies are needed not only to replicate
our findings but also to test if the our findings are valid in
the comparably small subgroup of non-COPD patients.
NPPV is a well-known treatment option for patients
with AHRF. Earlier studies have shown that in patients
with AECOPD, NPPV can reduce the risk of intubation,
reduce in-hospital mortality and shorten the hospital
stay [3–7]. Its use has been growing and more data has
appeared supporting the positive effects of the treat-
ment, even in other types of respiratory failure [21]. The
treatment is costly in terms of technical equipment and
surveillance, and not all patients can tolerate the treat-
ment or benefit from it [17]. Even if there are clinical
tools that have been shown to help in predicting the out-
come of NPPV treatment, the search for parameters that
can provide additional help in treatment decisions is im-
portant, both in regard to costs and patient comfort
[12–14, 33].
Because of its predictive value in relation to short term
mortality, our findings imply that the inflammatory bio-
marker IL-8 could potentially be used in the initial
evaluation of the patient with AHRF, to help choose the
most appropriate treatment. This potential clinical use
can be used on patients with AECOPD and even maybe
in other types of AHRF (Acute Heart Failure or Acute
Exacerbation of OHS). This is clinically important, as
the main cause for the AHRF is not always clear
when the patient arrives to the ER. GDF-15 showed
similar results as IL-8, but our analysis implies that it
is not an independent factor but dependent of IL-8 in
this clinical setting. CRP did not influence the correl-
ation between IL-8 and 28 days mortality, and it was
even not effected by the confounding factors age,
gender, BMI, blood analysis (pH, pO2, pCO2, lactate)
as well as respiratory rate at start of treatment or pri-
mary discharge diagnosis (Table 2). A high value of
IL-8 might thus prompt the physician to choose more
invasive treatment such as intubation. As many forms
of acute and chronic illnesses are characterized by en-
hanced inflammation, it is likely that high baseline
values of IL-8 and GDF-15 reflects not only a more
severe acute condition but most likely also more se-
vere chronic illness.
IL-8 is a chemokine that induces the migration of neu-
trophils to the airway and affects degranulation [28].
Both sputum and serum IL-8 have been targets for
Table 3 Relationship between Growth Differentiation Factor 15(GDF-15) and risk of 28-day mortality
GDF-15 on admission vs 28 days follow-up death (Model 1 and 2)
Continuous GDF-15 analysis
(per SD increment)
P-value Tertile 1 Tertile 2 Tertile 3 P for trend
N/N eventsb 46/13 15/1 16/3 15/9
HR (95% CI) (age and gender adjusted) 2.76 (1.37–5.56) 0.004 1.0 (ref) 1.21 (0.19–7.77) 3.48 (0.54–22.34) 0.124
HR (95% CI) (age, gender and CRP adjusted)a 3.48 (1.78–6.80) <0.001 1.0 (ref) 1.14 (0.16–8.21) 2.65 (0.36–19.41) 0.036
SD standard deviation, HR hazard ratio, CI confidence interval, CRP C-reactive protein
aBackward elimination model
bdeath within 28 days from admission
Fig. 1 Kaplan-Meier plot showing cumulative mortality during 28 days of follow-up. Tertile 1 denotes the lowest values of IL-8; and Tertile 3 the
highest values
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research in regards to COPD mortality and exacerba-
tions. A review by Koutsokera et al. summarized that IL-
8 levels in spontaneous sputum in patients with
AECOPD can be predictive of clinical severity, symp-
tomatic recovery and even presence of bacterial infec-
tion and its eradication [34]. Agusti et al. identified 6
inflammatory biomarkers (including IL-8) that were re-
lated to systemic inflammation, and patients with COPD
in which those biomarkers were elevated in serum
showed increased all-cause mortality and exacerbation
frequency, during three-year follow up time [35]. Lastly,
Shafiak et al. showed that in patients with AECOPD,
serum IL-8 had higher levels in non-responders of
NPPV vs. responders, where failure was defined as ter-
mination of NPPV trial and initiation of invasive mech-
anical ventilation. IL-8 was however not correlated to
presence of bacterial infection [36]. To our knowledge,
that is the only prior study that has studied IL-8 levels
and its correlation to AECOPD and NPPV treatment.
The combination of these results support that IL-8 can
possibly be used as a clinical predictor of response to
NPPV treatment in patients with AECOPD, although to
our knowledge, no prior study has focused on correl-
ation between IL-8 in serum and short-term mortality in
this patient group.
The GDF-15 protein is also a member of the inflam-
matory pathway, and is produced by multiple cells in re-
sponse to oxidative and inflammatory factors. In recent
years, studies have shown that GDF-15 levels can help in
predicting mortality and adverse events in patients with
cardiovascular diseases and other diseases [29]. Recent
studies have even evaluated the connection between
GDF-15 levels and AECOPD, in which patients with
AECOPD had higher baseline blood levels of GDF-15
and it is regarded as an independent predictor of the
presence of AECOPD [37, 38]. Our data did not confirm
that serum GDF-15 was an independent prognostic
factor for short-time mortality in patients with AHRF
who receive NPPV treatment, but suggested that it is
dependent of IL-8 levels. To our knowledge no other
study has addressed the role of GDF-15 in this clinical
setting.
The predictive value of IL-8 on 28 days mortality was
independent of the traditional biomarker CRP and it had
a comparatively stronger association, although CRP
levels also had an independent correlation to the end-
point. Our study does not allow any conclusions as to
whether or not the relationship between IL-8 and short
term mortality is causal, but in our opinion encourages
further mechanistic studies to better understand this
issue.
Our study has several limitations, the main one being
the relatively small sample size, which also results in
wide confidence intervals. Further studies are needed,
which should include a larger group of patients with a
larger spectrum of diagnoses and preferably even pa-
tients that are intubated if NPPV treatment is not suc-
cessful. Another limitation is that only 85% of the
patients did a chest radiography during the initial hours
of the NPPV treatment. Nonetheless, the radiological re-
sults did not have any correlation to 28 days mortality.
The group of patients in this study had a high percent-
age of the “Do Not Resuscitate” order (72%), compared
with an audit made by Roberts and al in UK (40%) [39].
A possible reason for this difference is that in the local
guidelines, the admitting physician is obligated to make
a resuscitation judgement if the patient is to be treated
with NPPV. 28 days mortality was (28%) and can be
regarded as more severely ill than groups of patients in
some other studies in the field [8, 19], but similar to that
reported in the UK audit (25% inhospital mortality) [39].
In this setting it is a challenge to recruit patients for re-
search projects. Nonetheless, it is our opinion that more
research in severely ill patients is necessary, to help clini-
cians make the choice between the use of demanding
treatment such as NPPV or go directly to intubation.
Our study did not include any patients that were later
intubated so we cannot make any assumption as to how
IL-8 values are effected by that. In our opinion it would
be interesting to raise that question in further studies,
and also evaluate the hypothesis that if IL-8 values do
not become lower during noninvasive or invasive re-
spiratory support, the prognosis would be poor in
regards to short term mortality.
Table 4 Relationship between IL-8/GDF-15 and risk of 28-day mortality in a subgroup of patients with AECOPD
IL-8 and GDF-15 on admission vs 28 days follow-up death – AECOPD subgroup
IL-8 GDF-15
Continuous analysis (per SD increment) P-value Continuous analysis (per SD increment) P-value
N/N eventsb 34/11 34/11
HR (95% CI) (age and gender adjusted) 4.16 (1.84–9.39) 0.001 3.10 (1.30–7.40) 0.011
HR (95% CI) (age, gender and CRP adjusted)a 4.34 (2.05–9.19) <0.001 3.28 (1.56–6.88) 0.002
AECOPD acute exacerbation of COPD, SD standard deviation, HR hazard ratio, CI confidence interval, CRP C-reactive protein
aBackward elimination model
bdeath within 28 days from admission
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Another limitation of the study is the heterogeneity of
the group. Subgroup analysis did not seem to influence
the results though and the largest subgroup of patients,
with AECOPD, have an even stronger association with
the endpoint. Since the other two subgroups with AHF
and AEOHS were so small in numbers, one should be
careful to interpret the results in that clinical setting.
The diagnosis of COPD and heart failure prior to admis-
sion came from the patients’ medical records, but some
data regarding spirometry and echocardiography was
not present. Nonetheless, the primary discharge diagno-
sis was assessed by the same internist in all cases, and
the probability of wrong diagnosis seems minimal be-
cause of the large amount of clinical data available dur-
ing the admission. In our opinion, the heterogeneity of
the group reflects the clinical setting in the ER where
the underlying medical condition resulting in respiratory
failure is commonly unknown, and the results can be ap-
plied in that context. Further studies of patients with
AHRF in regards of clinically important prognostic fac-
tors are relevant because the treatment with NPPV can
be costly and difficult for patients, and existing patient
selection tools do not always help in treatment decision.
Conclusion
Our results show that IL-8 in serum is a target to
explore further as a predictor of short-time mortality in
patients with Acute Hypercapnic Respiratory Failure and
Acute Exacerbation of COPD treated with Noninvasive
Positive Pressure Ventilation. Its use in the initial assess-
ment of this patient group should be addressed in stud-
ies with a larger number of patients but our result
suggests a use of IL-8 as a tool to help physicians in
treatment decisions.
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